BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06209736 (zaltenibart in C3 glomerulopathy or type I idiopathic…): BVCT ex-ante prediction vs. reported outcome

On 16 Oct 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 4 Aug 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably insignificant and commercially probably insufficient.

Clinical Trial

NCTID
NCT06209736
Drug Name
zaltenibart
Drug MoA
anti-MASP3 inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Urogenital Diseases
Indication
C3 glomerulopathy (C3G) or type I idiopathic immune complex mediated membrane proliferation glomerulonephritis (ICGN)
Human Patients
20
Sponsor
Novo Nordisk
Phase
Phase 2

Prediction of , index 2074

Prospective Prediction
Prediction Index
2074
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient (additive) clinical benefit in eGFR at month 6 moderately inferior to iptacopan for both ICGN and C3G)
Technical Prediction
FAILURE (statistically insignificant (additive) clinical benefit in UPCR at month 6 compared with placebo for ICGN) partial FAILURE (statistically maybe significant yet very weak (additive) clinical benefit in UPCR at month 6 compared with placebo for C3G)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
292 days in advance
Readout Data Interpretation
zaltenibart’s further development has probably discontinued given that the trial ended April 2026 without a public efficacy readout and C3G/ICGN no longer represented in Novo Nordisk's formal pipeline from Q2 2026
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably insignificant and commercially probably insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)
Phase
Phase 2
Status
Recruiting
Enrollment
20
Lead sponsor
Omeros Corporation
Conditions
C3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritis
Interventions
DRUG: OMS906 study drug
Design
Single group · None
Primary purpose
Treatment
Start
2024-03-01
Primary completion
2026-01
Completion
2026-04
Primary outcomes
  • To assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN. (48 weeks)

NCT06209736 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials